Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by HuntNGatheron Jun 10, 2020 10:42am

190 Views

Post# 31133120

RE:RE:Institutional Investors

Seeing that long list of insider selling or acting on their options and getting right around 60 cents over and over and over makes them not look like they are acting in bad faith with the retail investors and also with their new buddies at Echelon and BB. If they would have sold personal stakes up in the 70s or better, then this announcement came down, they would look like they were gaming it and insider trading issues would have arisen I suspect. Just can't do it when there is ink on paper somewhere and they know it. Driving the price down to something that looks comfortably like what is on the paper makes them look like they weren't at the wheel, but with volumes like that... they were.

Bullboard Posts

The top 10 Canadian medical stocks